Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer

International Journal of Biological Markers

Volumn 14, Issue 2, 1999, Pages 92-98

  Foa, Paolo ^a   Fornier, M ^a   Miceli, R ^b   Seregni, E ^b   Santambrogio, L ^a   Nosotti, M ^a   Massaron, S ^b   Cataldo, I ^b   Oldani, S ^a   Iurlo, A ^a   Caldiera, S ^a   Bombardieri, E ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

CEA; CYFRA 21.1; Non small cell lung cancer; NSE; SCC; TPA

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; SQUAMOUS CELL CARCINOMA ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; ENZYME ASSAY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNORADIOMETRIC ASSAY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTION AND FORECASTING; PREOPERATIVE EVALUATION; SQUAMOUS CELL CARCINOMA;

EID: 0033002559     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089901400206     Document Type: Article

References (36)

1. Mitsudomi T, Oyama T, Nishida K, et al. p53 nuclear immunostaining and gene mutations in non-small cell lung cancer and their effects on patient survival. Ann Oncol 1995; 6 (Suppl 3): S9-S13.
2. Mills NE, Fishman CL, Rom WN, Dubin N, Jacobson DR. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res 1995; 55: 1444-7.
3. Rosell R, Molina F, Moreno I, et al. Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in stage IIIA non-small cell lung cancer. Lung Cancer 1995; 12 (Suppl 1): S59-S70.
4. Rosell R, Monzo M, Molina F, et al. K-ras genotypes and prognosis in non-small cell lung cancer. Ann Oncol 1995; 6 (Suppl 3): S15-S20.
5. Fontanini G, Vignati S, Bigini D, et al. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small cell lung cancer. Br J Cancer 1995; 71: 1003-7.
6. Kanters SDJM, Lammers JWJ, Voest EE. Molecular and biological factors in the prognosis of non-small cell lung cancer. Eur Respir J 1995; 8: 1389-97.
7. Mountain CF. New prognostic factors in lung cancer. Chest 1995; 108: 246-54.
8. Roth JA. Molecular events in lung cancer. Lung Cancer 1995; 12 (Suppl 2): S3-S15.
9. Fishbach W, Jani B. Neuron-specific enolase in the diagnosis and therapy monitoring of lung cancer: a comparison with CEA, TPA, ferritin and calcitonin. Int J Biol Markers 1986; 1: 129-36.
10. De Angelis G, Bigioni D, Leonatti C, Pigorini F. Serum carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and neuron-specific enolase (NSE) for monitoring lung cancer and correlation with metastases. Tumor Marker Oncol 1988; 3: 15-20.
11. Gomm SA, Keevil BG, Thatcher N et al. The value of tumor markers in lung cancer. Br J Cancer 1988; 58: 797-804.
12. Nutini S, Capelli G, Benucci A, Catalani C, Nozzoli F. Serum NSE, CEA, CT, CA15.3 levels in human lung cancer. Int J Biol Markers 1990; 5: 198-202.
13. Walop W, Chretien M, Colman NC, et al. The use of biomarkers in the prediction of survival in patients with pulmonary carcinoma. Cancer 1990; 65: 2033-46.
14. Reeve JC. Clinical and biological relevance of lung tumor markers. Diagn Oncol 1991; 1: 305-15.
15. Bergman B, Brezicka FT, Engstrom CP, Larsson S. Clinical usefulness of serum assays of neuron-specific enolase, carcinoembryonic antigen and CA-50 in the diagnosis of lung cancer. Eur J Cancer 1993; 29A: 198-202.
16. Devine PL, Yarker JY, Kwum MF, et al. Serum markers CASA, CEA, CYFRA 21.1, MSA, NSE, TPA, and TPS in lung cancer. Int J Oncol 1994; 4: 1129-35.
17. Niklinski J, Furman M. Clinical tumor markers in lung cancer. Eur J Cancer Prev 1995; 4: 129-38.
18. Spinazzi A, Soresi E, Boffi R, et al. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer. Cancer Detect Prev 1994; 18: 209-20.
19. Vincent RG, Chu TM, Lane WW. The value of carcinoembryonic antigen in patients with carcinoma of the lung. Cancer 1979; 44: 685-91.
20. Niklinski J, Furman M, Laudanski J, Kozlowski M. Prognostic value of pretreatment CEA, SCC-Ag and CA 19.9 levels in sera of patients with non-small cell lung cancer. Eur J Cancer Prev 1992; 1: 401-6.
21. Buccheri FG, Ferrigno D, Sartoris AM, Violante B, Vola F, Curcio A. Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19.9. Cancer 1987; 60: 42-50.
22. Tapia FJ, Polak JM, Barbarosa AJA, et al. Neuron-specific enolase is produced by endocrine tumors. Lancet 1981; 1: 808-11.
23. Carney ND, Marangos PJ, Ihde DC. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet 1982; 1: 583-5.
24. Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 1997; 40: 1621-8.
25. Erbert W, Leichtweis B, Bulzebruck HY, Drings P. The role of IMx SCC assays in the detection and prognosis of primary squamous-cell carcinoma of the lung. Diagn Oncol 1992; 2: 203-10.
26. Buccheri FG, Ferrigno D. Usefulness of tissue polypeptide antigen in staging, monitoring and prognosis of lung cancer. Chest 1988; 93: 565-70.
27. Buccheri FG, Ferrigno D. Prognostic value of tissue polypeptide antigen in lung cancer. Chest 1992; 101: 1287-92.
28. Van Der Gaast A, Schoenmakers CHH, Kok TC, Blijenberg BG, Cornillie F, Splinter TAW. Evaluation of a new tumor marker in patients with non-small cell lung cancer: CYFRA 21.1. Br J Cancer 1994; 69: 525-8.
29. Wieskopf B, Demangeat C, Purohit A, et al. CYFRA 21.1 as a biologic marker of non-small cell lung cancer. Chest 1995; 108: 163-9.
30. Ebert W, Dienemann H, Fateh-Moghadam A, et al. Cytokeratin 19 fragment CYFRA 21.1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Eur J Clin Chem Clin Biochem 1994; 32: 189-99.
31. Harrell FE, Lee KL, Mark DB. Tutorial in biostatistics. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-87.
32. SAS/STAT User's guide, Version 6, fourth Edition, Volume 2, Cary, NC, SAS Institute Inc, 1989.
33. Statistical Sciences, S-PLUS Guide to Statistical and Mathematical Analysis, Version 3.3, Seattle, StatSci, a Division of MathSoft Inc., 1995.
34. Hanley JA, McNeil BJ. The meaning and use of the area under a Receiver Operating Characteristic (ROC) curve. Radiology 1982; 143: 29-36.
35. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularisation to metastasis of non-small cell lung cancer. Lancet 1992; 340: 145-6.
36. Macchiarini P, Fontanini G, Dumlet E, et al. Angiogenesis: an indicator of metastasis in non-small cell lung cancer invading the thoracic inlet. Ann Thorac Surg 1994; 57: 1534-9.